Introduction
Lung is a target organ for inhaled chemicals and carcinogens. Several enzymatic and non-enzymatic systems cooperate in the metabolism and disposition of these compounds.
Phase I xenobiotic-metabolizing enzymes (XMEs), in particular Cytochromes P450 (CYPs), catalyze the first step of xenobiotic processing via oxidation, reduction or hydrolysis reactions. Phase II XMEs conjugate xenobiotics or their phase I metabolites to hydrophilic endogenous substrates, making molecules more suitable for elimination. In general, biotransformation reactions are beneficial in that they help the pulmonary tissues to reduce the potential toxicity of inhaled toxicants. Sometimes, however, XMEs transform harmless substances into "bioactivated" metabolites which are highly reactive with endogenous macromolecules, causing cell death and gene mutations (Castell et al., 2005) . Transporters, mainly represented by the solute carriers (SLC) and ATP-binding cassette (ABC) families, mediate the entrance of xenobiotics into cells or facilitate the efflux of xenobiotics or their metabolites from cells. Tight coupling between metabolism and transport processes is ensured by ligand-activated transcription factors that control constitutive and inducible expression of XME and transporter genes in a coordinate manner. Two major nuclear receptors, namely the Pregnane X receptor (PXR) and Constitutive Androstane Receptor (CAR), and one member of the family of basic helix-loop-helix transcription factors, the Aryl hydrocarbon Receptor (AhR), are activated by xenobiotics and are therefore termed as xenosensors (Nakata et al., 2006) . Expression profiles of XMEs, transporters and nuclear receptors define the metabolic capacity of each tissue and may have consequences for cell defense against environmental chemicals but also for drug response. Recently, we characterized the mRNA expression level of 380 genes involved in the cellular processing of xenobiotics in pulmonary parenchyma (PP), bronchial mucosa (BM), and tumoral lung tissues (Leclerc et al., 2011) . These data allowed the identification of the major XME and transporter genes expressed in PP and BM, This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on July 13, 2012 as DOI: 10.1124 at ASPET Journals on June 23, 2017 dmd.aspetjournals.org Downloaded from DMD # 46896 5 and confirmed that AhR was the predominant xenosensor expressed in human lung.
Significant differences in gene expression between BM and PP, and a global decrease in gene expression in tumoral lung tissues were also pointed out, suggesting distinct susceptibility to xenobiotics and their toxic effects between these tissue types.
Human cell lines are still widely used to study the impact of toxicants on lung or to test new therapeutics including anti-cancer drugs. Primary cells are also used but are more difficult to obtain and have limited growth activity. However there is some evidence that primary cells are the best experimental models for in vivo situations. Expression of xenobiotic/drug-metabolizing enzymes has been extensively studied in many human hepatic cell lines and compared with primary human hepatocytes or human liver slices. Large variations in the expression of xenobiotic metabolizing enzymes have been observed between hepatic cell lines and primary hepatocytes, with the complete absence or much lower abundance of certain enzymes in hepatic cell lines (LeCluyse, 2001; Gómez-Lechón et al., 2004; Olsavsky et al., 2007) . However, although the perfect hepatoma cell line is not yet available, the expression of many drug metabolizing genes was similar in the HepaRG cell line and primary hepatocytes, suggesting that this cell line may be a reliable surrogate to human hepatocytes for studies of xenobiotic metabolism and toxicology (Aninat et al., 2006; Guillouzo et al., 2007; Hart et al., 2010) .
In contrast to in vitro liver systems, the level of expression of genes involved in the metabolism and disposition of xenobiotics in lung cell models is much less documented.
Many lung cell lines are available for toxicity studies but their metabolic capacities are not well defined and differences in gene expression compared to lung primary cells or tissues are very limited. The adenocarcinoma A549 cell line is probably the best characterized and the most widely used (Foster et al., 1998; Hukkanen et al., 2000) . Quantitative RT-PCR analyses detected transcript levels for several CYP in this cell line but at levels lower than those found This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on July 13, 2012 as DOI: 10.1124 at ASPET Journals on June 23, 2017 dmd.aspetjournals.org Downloaded from DMD # 46896 6 in human lung tissue (Castell et al., 2005) . Moreover, few data are available about phase II enzymes or transporters in A549 cells.
In the current study, we aimed to assess the metabolic capacities of ten commonly used lung cell lines (A549, H292, H358, H460, H727, Calu-1, 16HBE, 1 HAEO, , and four primary cultures of human bronchial epithelial cells. The mRNA level of almost all of genes encoding XMEs, transporters, nuclear receptors and transcription factors involved in the cellular processing of xenobiotics was measured using a high throughput quantitative real-time RT-PCR strategy based on TaqMan Low Density Arrays (TLDA).
Expression results were then compared to those previously obtained in human non tumoral (bronchial mucosa and pulmonary parenchyma) and tumoral (adenocarcinoma or squamous cell carcinoma) lung tissues.
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Materials and methods

Lung tissue samples
Twelve patients undergoing partial or complete lung resection for Non Small Cell Lung Cancer (NSCLC) were included in this study. Informations related to each patient, histopathology of tumor samples and transcript profiling have been previously described (Leclerc et al., 2011 ). An informed consent was obtained for each patient. None of the patients were treated with preoperative radiotherapy or chemotherapy. For each patient, three tissue samples were collected: one from the tumor (adenocarcinoma (AC) or squamous cell carcinoma (SCC) and two from macroscopically healthy areas of lobar bronchi (BM) and distal pulmonary parenchyma (PP), both of which were taken remotely from the tumor. After surgical resection, samples were immediately submerged in RNAlater™ Solution (Ambion, Courtaboeuf, France) to avoid RNA degradation, stored at 4°C for 24 h and then at -20°C until used. Four additional BM specimens namely P13.B, P14.B, P15.B, and P16.B, were analyzed; they correspond to tissues samples used for primary cultures of human bronchial epithelial cells (HBEC 1, 2, 3, and 4, respectively).
Cell culture
A549, Calu-1, H292, H358, H460, and H727 cell lines were purchased from the American Type Culture Collection (ATCC). The immortalized bronchial epithelial cells 1HAEO and 16HBE were generous gifts from Dr P. Gosset (INSERM U1019, Lille, France).
The immortalized bronchial epithelial cells BEAS-2B and the L-132 cell line were generous gifts from Pr P. Shirali (ULCO, EA4492, Dunkerque, France). The A549 and H358 cells were derived from lung adenocarcinomas, the Calu-1 cells from a lung squamous cell carcinoma, the H292 cells from a lymph node metastasis of a pulmonary mucoepidermoid carcinoma, the H460 cells from a large cell carcinoma, the H727 cells from a carcinoid tumour, and the LThis article has not been copyedited and formatted. The final version may differ from this version. HBECs were derived from bronchial tissues of four patients undergoing surgery for lung carcinomas. After surgical resection, macroscopically healthy areas of lobar bronchi were immediately immersed in a nutrient medium containing DMEM, 1% Penicillinstreptomycin, and 2% fungizone, then stored at 4°C until used. Bronchial segments were rinsed twice with cold PBS and processed for mucosa isolation using a sterile scalpel. Small pieces of BM (about 2 mm 2 ) were used as a source of primary cell. They were placed in 9 cm 2 plates coated with 0.8 % collagen G in the presence of 500 µl of a serum free medium (Small Airway Epithelial Cell Medium, Promocell, Heidelberg, Germany) supplemented with 1%
penicillin-streptomycin and 2% fungizone. After an adherence period of 24 hours, 2 ml of culture medium were added and were changed every 2-3 days. Epithelial cells grown from bronchial explants reached 100% confluence in about 10 days. After trypsinization, cells were gathered, reseeded in new 9 cm 2 plates coated with collagen and cultured until confluency.
RNA Isolation
RNA extractions from lung tissues were performed as previously described (Leclerc et al., 2011) . For cell culture, 600 µl of RLT lysis buffer supplemented with 1% mercaptoethanol was directly added to the cell dishes. Total RNAs were isolated using the RNeasy plus Mini Kit ™ (Qiagen, Courtaboeuf, France) according to the instructions of the manufacturer. The yield of the extracted RNA was determined by measuring the optical density at 260 nm with the BioSpec-nano spectrophotometer (Shimadzu, Champs sur Marne, France). The purity and quality of RNA were evaluated using the Experion automated electrophoresis station (Biorad, Marnes-la-Coquette, France). High quality RNA with RQI (RNA Quality Indicator) greater than 9.0 were used for the study.
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Quantitative real-time PCR
Gene expression was quantified using custom TaqMan ™ Low Density Arrays (TLDA, Applied Biosystems). This real-time PCR-based technique consists in a 384-well micro fluidic card preloaded with sets of primers and 6-FAM labeled TaqMan MGB probes previously selected from predesigned TaqMan ™ Gene Expression Assays (Applied Biosystems). We chose a configuration with 380 different assays, the last 4 wells being dedicated to the control assay (in quadruplicate).
TLDA design
TLDA were configured with 380 assays for genes encoding proteins known or suspected to be involved in the metabolism of xenobiotics, to govern the cellular entry or efflux of these compounds and/or their metabolites, or to coordinate the metabolism and transport processes (Leclerc et al., 2011) . This set of genes comprised 137 genes of phase I enzymes (including 56 CYPs), 69 genes of phase II enzymes, 103 genes of transporters (including 31 ABC and 62 SLC transporters), 48 genes of nuclear receptors and transcription factors (including coactivators and corepressors), and 23 miscellaneous genes (including 9 metallothioneins). It should be noted that some of the CYP genes analyzed in this study encode enzymes (families CYP4 to CYP51) that are rather involved in endogenous pathways such as the biosynthesis of bile acids and steroid hormones, the metabolism of eicosanoids, vitamin D and retinoic acid. As they control the levels of endogenous substrates that are 10 sometimes associated with tumor promotion or progression, it could be stated that these CYP enzymes participate indirectly in environmental carcinogenesis (Nebert et al., 2006) .
TLDA procedure
The TLDAs were loaded with each cDNA template mixed with 2X TaqMan™ 
Analysis of gene expression
The detection threshold was set at 0.3 for all genes, except 13 genes for which a threshold at 0.3 would have led to inaccurate quantification (Leclerc et al., 2011 Gene expression profiles of the different lung cell models are presented in Table 1 .
Expression profiling in non-tumoral and tumoral lung tissues is also described in this Table. Out of the 380 genes that we studied, 57 genes were regarded as not expressed (Ct value above 35) in all cultured lung cell models. Thirty-seven of these genes were also undetectable in lung tissues. In primary cells, 140 genes (36.8 %) were considered not expressed. They The phase II XME genes that exhibited the highest mRNA levels in primary cells encode the glutathione S-transferases GSTK1, GSTO1, GSTP1, MGST1 and MGST3, the methyltransferases COMT and TPMT, the N-acetyltransferase NAT5, the sulfotransferase SULT2B1, and the mercaptopyruvate sulfurtransferase MPST. Apart from SULT2B1, these genes also presented a significant level of expression in other lung cell models and lung tissue specimens. Surprisingly, GSTA1/GSTA2 and INMT, which were among the genes with the highest expression levels in BM and PP, respectively, were not detectable in most lung cell models.
Concerning transporters, 13 genes, namely ABCA1, ABCB2, ATP6V0C, MVP, SLC2A1, SLC3A2, SLC7A5, SLC7A11, SLC16A1, SLC31A1, SLC38A1, SLC38A2, and SLC38A5, were highly expressed in lung primary cultures. ABCA1 and/or SLC38A5 exhibited lower mRNA levels in most cell lines, as well as SLC7A5, SLC7A11, and SLC16A1 in human lung tissues. Except for the A549 cell line, the AQP1 and/or SLCO2B1 mRNAs, which were abundant in non tumoral lung tissues, were not detected in lung cell cultures. In the four primary cultures of HBEC, most of the genes showed very similar mRNA expression levels between individuals, as assessed by a coefficient of variation (CV) lower than 5 % for 85.3 % of the genes. Only 8.2% of the genes exhibited high variability (CV ≥ 10%) ( Table 2 ). Interindividual variations in mRNA expression were particularly high for GSTM1 and GSTT1 with CV= 19.8 % and 28.6 %, respectively.
Differential expression profiling between primary lung cells, lung cell lines and lung tissues.
To reveal homologies of expression patterns among the lung cell models, a similarity matrix was evaluated by a pairwise comparison of the samples (Table 3) Differences in mRNA levels between in vitro lung models and lung tissues were measured for each gene. The number of genes differentially expressed (i.e. genes that exhibit at least a 4-fold difference in expression) is described in Table 4 . Among all the cells tested, 16 the L-132 cell line had expression levels the most distant from those observed in vivo, since it exhibited the highest number of differentially expressed genes compared with non tumoral lung tissues. In comparison with BM, the primary and BEAS-2B cells showed the lowest number of differentially expressed genes. Compared to PP, the H292 and BEAS-2B cells showed the lowest number of differentially expressed genes.
Gene expression profiles of in vitro models were also compared with those of tumour samples ( Table 4 (i.e. AIP, ARNT, P23 (PTGES3) and HSP90) were as widely expressed in lung cell models as in lung tissues. The CYP1A1 isoform that is poorly or not expressed in bronchial tissues in basal conditions (Leclerc et al., 2010 (Leclerc et al., & 2011 Willey et al., 1997; Thum et al., 2006) exhibited higher levels of expression in most cell models. CYP1B1, another isoform of the CYP1 family, was also upregulated in vitro, especially in the 16HBE and BEAS-2B cells. In contrast to CYP1 enzymes, other procarcinogen activating CYPs previously reported as highly and/or specifically expressed in bronchial mucosa, such as CYP2F1, CYP4B1 and to a lesser extent CYP2B6, (Lanza and Yost, 2001; Baer et al., 2005; Hodgson and Rose, 2007) , are significantly underexpressed or not expressed in most lung cells. Similarly, some genes encoding phase II enzymes and found at high level of expression in BM were markedly downregulated (GSTA1-2 in A549 and/or primary cells) or not detected in lung cell models (GSTA1-3). The loss of expression of some GSTs and CYPs in lung cell models should be considered when studying the in vitro impact of inhaled toxicants.
In vitro cell-based models are also currently used in mechanistic studies of membrane transport and the pharmaceutical screening of drug candidates. Membrane transporters are involved in the uptake and the efflux of chemotherapeutic agents and therefore contribute to drug resistance (Chang et al., 2011) . In a previous study, mRNA expression levels of 31 drug transporters were investigated in established cell lines (A549, Calu-3, 16HBE, BEAS-2B) and primary cultures of lung epithelial cells, using a conventional semi-quantitative RT-PCR methodology (Endter et al., 2009 ). In accordance with our results, the authors highlighted disparities between the lung cell models. However, discrepant findings concerning the level of expression of some genes were observed, probably because of the varying sensitivity and specificity of the methods used to detect gene expression.
Our study revealed differences in expression profiles between lung tumors and lung cell models. Evidence that ABC transporters play a significant role in clinical drug resistance et al., 2012) . Regarding the ABCC6 and ABCC9 genes, while they were moderately expressed in lung tissues, we failed to detect their mRNAs in most lung cell models.
SLCs typically mediate uptake and chemosensitivity for hydrophilic drugs. The first report of SLC-mediated transport of anticancer drugs dealt with the antifolate drug methotrexate, which is transported by members of the SLC19A family (SLC19A1-3) (Goldman et al., 1985) . Decrease or loss of SLC19A1 gene expression has been detected in cancer cell lines made resistant to antifolates in vitro (Gifford et al., 2002) . We observed that 
